BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Price & Overview

BIT:1BSX • US1011371077

Current stock price

63 EUR
-1.4 (-2.17%)
Last:

The current stock price of 1BSX.MI is 63 EUR. Today 1BSX.MI is down by -2.17%. In the past month the price decreased by -30.77%.

1BSX.MI Key Statistics

1-Month Range62.6 - 92.2
Current 1BSX.MI stock price positioned within its 1-month range.
Market Cap
93.485B
P/E
23.86
Fwd P/E
20.80
EPS (TTM)
2.64
Dividend Yield
N/A

1BSX.MI Stock Performance

Today
-2.17%
1 Week
-23.73%
1 Month
-30.77%
3 Months
-10.64%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1BSX.MI Stock Chart

BOSTON SCIENTIFIC CORP / 1BSX Daily stock chart

1BSX.MI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to 1BSX.MI.


Chartmill TA Rating
Chartmill Setup Rating

1BSX.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI. 1BSX.MI scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1BSX.MI Earnings

On February 4, 2026 1BSX.MI reported an EPS of 0.8 and a revenue of 5.29B. The company beat EPS expectations (1.62% surprise) and missed revenue expectations (-0.88% surprise).

Next Earnings DateApr 21, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$0.80
Revenue Reported5.286B
EPS Surprise 1.62%
Revenue Surprise -0.88%

1BSX.MI Forecast & Estimates

40 analysts have analysed 1BSX.MI and the average price target is 91.33 EUR. This implies a price increase of 44.97% is expected in the next year compared to the current price of 63.

For the next year, analysts expect an EPS growth of 14.65% and a revenue growth 10.94% for 1BSX.MI


Analysts
Analysts85.5
Price Target91.33 (44.97%)
EPS Next Y14.65%
Revenue Next Year10.94%

1BSX.MI Groups

Sector & Classification

Index Membership

1BSX.MI Financial Highlights

Over the last trailing twelve months 1BSX.MI reported a non-GAAP Earnings per Share(EPS) of 2.64. The EPS increased by 21.51% compared to the year before.


Income Statements
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Industry RankSector Rank
PM (TTM) 14.44%
ROA 6.64%
ROE 11.96%
Debt/Equity 0.46
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%15.9%
EPS 1Y (TTM)21.51%
Revenue 1Y (TTM)19.88%

1BSX.MI Ownership

Ownership
Inst Owners94.17%
Shares1.48B
Float1.48B
Ins Owners0.16%
Short Float %N/A
Short RatioN/A

About 1BSX.MI

Company Profile

1BSX logo image Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Company Info

IPO: 1992-05-19

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS US

Employees: 59000

1BSX Company Website

1BSX Investor Relations

Phone: 13026365400

BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ

What does BOSTON SCIENTIFIC CORP do?

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.


What is the current price of 1BSX stock?

The current stock price of 1BSX.MI is 63 EUR. The price decreased by -2.17% in the last trading session.


Does 1BSX stock pay dividends?

1BSX.MI does not pay a dividend.


What is the ChartMill technical and fundamental rating of 1BSX stock?

1BSX.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the analyst forecast for 1BSX.MI stock?

40 analysts have analysed 1BSX.MI and the average price target is 91.33 EUR. This implies a price increase of 44.97% is expected in the next year compared to the current price of 63.


What is the GICS sector and industry of 1BSX stock?

BOSTON SCIENTIFIC CORP (1BSX.MI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Would investing in BOSTON SCIENTIFIC CORP be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1BSX.MI.